EUVIMEDEUVIMED entdecken
Crossref

HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer

Daniel Xia iD, Frank Kuo, Melissa Hughes, Neal Lindeman, Danielle Manning, Janet Files, Sarah Strauss, Greg Kirkner, Ayesha Mohammed-Abreu, Eric Winer, Sara M Tolaney, Nancy U Lin und 1 weitere

American Journal of Clinical Pathology · 2024

DOI: 10.1093/ajcp/aqad167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Daniel Xia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Health Network, Toronto,Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, High-Throughput Nucleotide Sequencing, In Situ Hybridization, Fluorescence. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Specialized Program of Research Excellence, Dana-Farber Cancer Institute Breast Oncology Center, Harvard Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

A combination of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is the current standard of care for HER2 evaluation in breast cancer. Here, we investigate the potential clinical utility of next-generation sequencing (NGS)–derived HER2/ERBB2 copy number (CN) data for predicting HER2 status as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.

Methods

In total, 294 locally recurrent and metastatic breast cancers previously tested by targeted hybrid capture–based NGS and by HER2 IHC/FISH were included. Analyses focused on the ERBB2 median log2 ratios and start-end genomic coordinates from NGS, average HER2 CN and HER2/CEP17 ratios from FISH, and the HER2 IHC scores. We also determined a more stringent log2 ratio cutoff to predict HER2-positive status with 100% specificity.

Results

Sixty-four (22%) cases were HER2 positive and 230 (78%) were HER2 negative by ASCO/CAP guidelines. The ERBB2 median log2 ratios from NGS strongly correlated with HER2 status by IHC/FISH (area under receiver operator characteristic curve = 0.951). ERBB2 log2 ratio more than 1.7 was 100% specific for HER2-positive results by IHC/FISH. Start and end genomic coordinates for regions of gain near ERBB2 by NGS also predicted HER2 status.

Conclusions

Copy number data from our NGS panel strongly correlate with HER2 status. Using a stringent cutoff, ERBB2 log2 ratio accurately predicts HER2 positivity with high specificity. The NGS CN assessment may have utility in determining HER2 status in certain clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesHigh-Throughput Nucleotide SequencingIn Situ Hybridization, FluorescenceDNA Copy Number VariationsHumansFemaleImmunohistochemistryGene DosageBiomarkers, TumorMiddle Aged

Stichwörter der Autor:innen

ERBB2FISHHER2breast cancercopy numberimmunohistochemistrynext-generation sequencing

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, University Health Network, Toronto,Canada.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA, US.
  • Breast Oncology, Dana Farber Cancer Institute, Boston, MA, US.
  • Pathology & Laboratory Medicine, Weill Cornell Medicine, New York, NY, US.
  • Yale Cancer Center, New Haven, CT, US.

ORCID-Profile: Daniel Xia

Förderung

  • Specialized Program of Research Excellence
  • Dana-Farber Cancer Institute Breast Oncology Center
  • Harvard Cancer Center

Zitieren

APA

Xia, D., Kuo, F., Hughes, M., Lindeman, N., Manning, D., Files, J., Strauss, S., Kirkner, G., Mohammed-Abreu, A., Winer, E., Tolaney, S. M., Lin, N. U., & Dillon, D. A. (2024). HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad167

Vancouver

Xia D, Kuo F, Hughes M, Lindeman N, Manning D, Files J, et al. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad167

BibTeX
@article{Xia2024,
  author = {Xia, Daniel and Kuo, Frank and Hughes, Melissa and Lindeman, Neal and Manning, Danielle and Files, Janet and Strauss, Sarah and Kirkner, Greg and Mohammed-Abreu, Ayesha and Winer, Eric and Tolaney, Sara M and Lin, Nancy U and Dillon, Deborah A},
  title = {HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer},
  journal = {American Journal of Clinical Pathology},
  year = {2024},
  doi = {10.1093/ajcp/aqad167}
}
Kostenlos starten →